Race Oncology initiates Australian site for Phase I solid tumour trial

3 min read | March 28, 2025 07:09 PM AEDT | By Team Kalkine Media

Google News:

Race Oncology initiates Australian site for Phase I solid tumour trial — Image source: shutterstock

Recent News

Rare Earths' Next Trigger: What the Market May Be Missing

Rare Earth Stocks Are Stirring Again — But What’s Really Changed?

ASX Penny Stocks: Where the Next Market Story Could Emerge

Hidden Signals Fueling the Next Wave of ASX Penny Stocks

Make Kalkine Media
My Trusted Source

Highlights:

Race Oncology Ltd establishes an Australian clinical site for its Phase 1 trial.

The study focuses on testing RC220 in combination with chemotherapy.

Trial to assess safety, dosage, and impact on cancer progression.

Race Oncology Ltd has taken a significant step in its ongoing clinical research by establishing its first Australian trial site for the Phase 1 study of RC220, a reformulated cancer treatment. This study will assess the drug in patients with advanced solid tumours.

The Southside Cancer Care Centre in Miranda, New South Wales, has been selected as the initial location for the trial. Additional sites are planned across Australia, Hong Kong, and South Korea. The commencement of patient recruitment is subject to governance approvals.

Focus on RC220 and Chemotherapy Combination

RC220 will be tested in combination with doxorubicin, a widely used chemotherapy drug. The study aims to evaluate the safety profile, determine the appropriate dosage, and observe the drug’s pharmacokinetics. The combination therapy is also being examined for its effects on tumour progression and heart health.

The trial will follow an open-label format, meaning both researchers and participants will be aware of the administered treatment. This approach enables efficient monitoring of treatment outcomes. A key area of investigation is the impact of RC220 on the m6A RNA pathway, a biological process linked to cancer.

Innovative Trial Design for Enhanced Efficiency

A Bayesian trial design has been implemented, allowing for adaptive decision-making and streamlined study progression. This methodology provides flexibility in adjusting trial parameters based on real-time data.

Chief Executive Daniel Tillett emphasized the significance of this milestone in advancing clinical research efforts. The Southside Cancer Care Centre serves as a central site in Australia, with preparations underway to expand the study across multiple locations.

Development of a New Chemotherapy Formulation

RC220 is a reformulated version of bisantrene, a chemotherapy compound originally developed decades ago. Race Oncology aims to refine its use as an alternative to traditional anthracyclines such as doxorubicin. The goal is to maintain the drug’s anticancer properties while reducing adverse effects on the heart.

The study consists of two stages. The first phase will focus on dose escalation to establish an optimal dosage. Once identified, additional participants will be enrolled to further examine safety aspects and potential benefits in tumour reduction.

Regular updates on trial progress will be provided, though individual patient data will not be disclosed. Beyond this study, Race Oncology is also exploring additional applications of RC220, including its role in treating acute myeloid leukaemia.

With collaborations involving various international research institutions, Race Oncology continues its efforts to expand treatment options within the healthcare stocks sector.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.